GF Fund Management CO. LTD. Invests $259,000 in Insmed Incorporated (NASDAQ:INSM)

GF Fund Management CO. LTD. acquired a new position in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 3,756 shares of the biopharmaceutical company's stock, valued at approximately $259,000.

Several other institutional investors have also recently added to or reduced their stakes in INSM. Nisa Investment Advisors LLC boosted its position in shares of Insmed by 5.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,533 shares of the biopharmaceutical company's stock worth $244,000 after buying an additional 183 shares during the period. Avior Wealth Management LLC purchased a new position in Insmed during the 4th quarter valued at about $157,000. Blue Trust Inc. grew its position in Insmed by 25.7% in the 4th quarter. Blue Trust Inc. now owns 2,462 shares of the biopharmaceutical company's stock valued at $180,000 after acquiring an additional 503 shares in the last quarter. KBC Group NV increased its stake in Insmed by 59.5% during the fourth quarter. KBC Group NV now owns 6,873 shares of the biopharmaceutical company's stock worth $475,000 after purchasing an additional 2,563 shares during the period. Finally, Moody Aldrich Partners LLC purchased a new position in shares of Insmed in the fourth quarter valued at approximately $2,449,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on INSM shares. Jefferies Financial Group began coverage on shares of Insmed in a report on Tuesday, May 13th. They set a "buy" rating and a $105.00 target price on the stock. Cantor Fitzgerald reiterated an "overweight" rating on shares of Insmed in a research note on Wednesday, February 19th. Guggenheim reissued a "buy" rating and set a $101.00 target price on shares of Insmed in a research note on Tuesday, February 25th. JPMorgan Chase & Co. upped their price target on Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a report on Friday, February 7th. Finally, UBS Group decreased their price objective on Insmed from $110.00 to $109.00 and set a "buy" rating for the company in a research note on Friday, May 9th. One research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat, Insmed presently has an average rating of "Moderate Buy" and an average target price of $94.63.

Insmed Stock Up 4.3%

Shares of Insmed stock traded up $2.85 during trading hours on Thursday, hitting $69.21. The company had a trading volume of 1,844,068 shares, compared to its average volume of 2,216,430. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The company's 50-day moving average is $69.97 and its two-hundred day moving average is $72.94. The company has a market cap of $12.61 billion, a P/E ratio of -12.38 and a beta of 0.84. Insmed Incorporated has a twelve month low of $45.85 and a twelve month high of $84.91.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.36) by ($0.06). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The company had revenue of $92.82 million during the quarter, compared to analyst estimates of $91.63 million. During the same quarter in the prior year, the company earned ($1.06) EPS. The business's revenue was up 22.9% on a year-over-year basis. Analysts anticipate that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Insmed news, Director Clarissa Desjardins bought 1,130 shares of Insmed stock in a transaction dated Wednesday, May 21st. The stock was acquired at an average cost of $66.35 per share, with a total value of $74,975.50. Following the completion of the acquisition, the director now owns 3,025 shares of the company's stock, valued at approximately $200,708.75. This represents a 59.63% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO William Lewis sold 21,057 shares of the business's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $67.65, for a total value of $1,424,506.05. Following the completion of the transaction, the chief executive officer now owns 314,230 shares in the company, valued at $21,257,659.50. This trade represents a 6.28% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 153,098 shares of company stock worth $10,724,192 in the last quarter. 3.00% of the stock is owned by insiders.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.